Clinical trial of TACE with oxaliplatin regimen in continuous hepatic artery chemotherapy combined with sorafenib in the treatment of intermediate and advanced primary liver cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030303

Enrollment

Unknown

Registered

2020-02-28

Start date

2012-02-01

Completion date

Unknown

Last updated

2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary liver cancer

Interventions

Case series:TACE+HAIC+sorafenib

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) aged 18-75 years; (2) Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; (3) Child-Pugh class A or B; (4) one HCC intermediate and advanced; (5) white blood cell counts >3x10^9/L and neutrophil counts >1.5x10^9/L; (6) serum creatinine 45%.

Exclusion criteria

Exclusion criteria: (1) currently had other malignancies; (2) uncontrollable infections (>2 grade infections; infections requiring antibiotic, antifungal, or antiviral interventions; infections requiring radiological or surgical interventions; infections with life-threatening consequences; or infections requiring urgent interventions); (3) pregnancy or breastfeeding; (4) previous sorafenib treatment; (5) severe allergies to contrast agents or other drugs.

Design outcomes

Primary

Measure	Time frame
overall survival;	—

Countries

China

Contacts

Public ContactXu Zhu

Peking University Cancer Hospital

drzhuxu@163.com+86 010 88196330

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026